Chimeric vaccines designed by immunoinformatics-activated polyfunctional and memory T cells that trigger protection against experimental visceral leishmaniasis.

Many vaccine candidates against visceral leishmaniasis (VL) have been proposed; however, to date, none of them have been efficacious for the human or canine disease. On this basis, the design of leishmaniasis vaccines has been constantly changing, and the use of approaches to select specific epitope...

Descripción completa

Detalles Bibliográficos
Autores: Brito, Rory Cristiane Fortes de, Ruiz, Jeronimo Conceição, Cardoso, Jamille Mirelle de Oliveira, Ostolin, Thais Lopes Valentim Di Paschoale, Reis, Levi Eduardo Soares, Mathias, Fernando Augusto Siqueira, Soares, Rodrigo Dian de Oliveira Aguiar, Roatt, Bruno Mendes, Oliveira, Rodrigo Corrêa de, Resende, Daniela de Melo, Reis, Alexandre Barbosa
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:Brasil
Institución:Universidade Federal de Ouro Preto (UFOP)
Repositorio:Repositório Institucional da UFOP
Idioma:inglés
OAI Identifier:oai:repositorio.ufop.br:123456789/13647
Acceso en línea:http://www.repositorio.ufop.br/jspui/handle/123456789/13647
https://doi.org/10.3390/vaccines8020252
Access Level:acceso abierto
Palabra clave:Reverse vaccinology
Leishmania infantum
Rational design of vaccines
Descripción
Sumario:Many vaccine candidates against visceral leishmaniasis (VL) have been proposed; however, to date, none of them have been efficacious for the human or canine disease. On this basis, the design of leishmaniasis vaccines has been constantly changing, and the use of approaches to select specific epitopes seems to be crucial in this scenario. The ability to predict T cell-specific epitopes makes immunoinformatics an even more necessary approach, as in VL an efficient immune response against the parasite is triggered by T lymphocytes in response to Leishmania spp. immunogenic antigens. Moreover, the success of vaccines depends on the capacity to generate long-lasting memory and polyfunctional cells that are able to eliminate the parasite. In this sense, our study used a combination of different approaches to develop potential chimera candidate vaccines against VL. The first point was to identify the most immunogenic epitopes of Leishmania infantum proteins and construct chimeras composed of Major histocompatibility complex (MHC) class I and II epitopes. For this, we used immunoinformatics features. Following this, we validated these chimeras in a murine model in a thorough memory study and multifunctionality of T cells that contribute to a better elucidation of the immunological protective mechanisms of polyepitope vaccines (chimera A and B) using multicolor flow cytometry. Our results showed that in silico-designed chimeras can elicit polyfunctional T cells producing T helper (Th)1 cytokines, a strong immune response against Leishmania antigen, and the generation of central and effector memory T cells in the spleen cells of vaccinated animals that was able to reduce the parasite burden in this organ. These findings contribute two potential candidate vaccines against VL that can be used in further studies, and help in this complex field of vaccine development against this challenging parasite.